Entera Bio Ltd. (ENTX)
$
2.82
+0.09 (3.19%)
Key metrics
Financial statements
Free cash flow per share
-0.1430
Market cap
107.3 Million
Price to sales ratio
646.4394
Debt to equity
0.0118
Current ratio
10.4723
Income quality
0.6278
Average inventory
0
ROE
-0.4275
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Entera Bio Ltd. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing orally delivered large molecule therapeutics to address unmet medical needs. The company incurred an income tax expense of $14,000.00 indicating its tax obligations. The cost of revenue for the company is $172,000.00 showcasing its production and operational expenses. The gross profit ratio is 0.05 reflecting the efficiency of the company's production and sales operations. In terms of investment income, the company earned an interest income of $58,000.00 which highlights its financial investments. The diluted EPS is -$0.25 accounting for potential share dilution. Entera's lead product candidates include EB612, currently in Phase II clinical trials for hypoparathyroidism, and EB613, which has completed Phase II clinical trials for osteoporosis and is also in Phase I clinical trials for the treatment of non-union fractures. Additionally, the company has established a research collaboration and license agreement with Amgen Inc. to further the development of clinical candidates in the field of inflammatory diseases and other serious illnesses. Founded in 2009, Entera Bio Ltd. is based in Jerusalem, Israel. The stock is affordable at $1.80 making it suitable for budget-conscious investors. It belongs to the Healthcare sector, driving innovation and growth, while being a key player in the Biotechnology industry, contributing significantly to the overall market landscape. With a market capitalization of $128,770,734.00 the company is classified as a small-cap player. Moreover, the stock has a low average trading volume of 142,945.00 indicating lower market activity. This profile reveals a firm engaged in critical therapeutic advancements, while also maintaining a financial structure that supports both operations and potential future growth, appealing to stakeholders seeking investment opportunities in promising health solutions.
Is Entera Bio Ltd. (ENTX) a good investment?
Investing in Entera Bio Ltd. (ENTX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Entera Bio Ltd. (ENTX)'s stock forecast?
Analysts predict Entera Bio Ltd. stock to fluctuate between $1.50 (low) and $2.95 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Entera Bio Ltd.'s market capitalization?
As of 2025-10-30, Entera Bio Ltd.'s market cap is $128,770,734, based on 45,663,381 outstanding shares.
How does Entera Bio Ltd. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Entera Bio Ltd. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Entera Bio Ltd. (ENTX) stock?
To buy Entera Bio Ltd. (ENTX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ENTX. Place an order (Market, Limit, etc.).
What is the best time to invest in Entera Bio Ltd.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Entera Bio Ltd. perform in the last earnings report?
Revenue: $181,000 | EPS: -$0.25 | Growth: -19.35%.
Where can I find Entera Bio Ltd.'s investor relations reports?
Visit https://www.enterabio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Entera Bio Ltd.?
You can explore historical data from here
What is the all-time high and low for Entera Bio Ltd. stock?
All-time high: $5.84 (2021-08-10) | All-time low: $0.47 (2022-11-11).
What are the key trends affecting Entera Bio Ltd. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in women 10 years post-menopause
fool.com
Entera Bio (ENTX 1.11%), a clinical-stage biotech specializing in oral delivery of protein and peptide drugs, released its earnings for the second quarter of fiscal 2025 on August 8, 2025. The most notable news was a better-than-expected GAAP earnings per share of $0.06, compared to Wall Street estimates for a GAAP loss of $(0.11).
globenewswire.com
JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S. Food and Drug Administration (FDA) agreed with the Company's proposal that the NDA marketing application filing for EB613 would be supported by a single multinational, randomized, double-blind, placebo-controlled, 24 month phase 3 study in women with postmenopausal osteoporosis, where change in total hip BMD is evaluated as the primary endpoint, and incidence of new or worsening vertebral fractures is evaluated as the key secondary endpoint. This marks a shift from precedent placebo-controlled phase 3 studies of new osteoporosis drugs which required incidence of fracture as the primary endpoint.
globenewswire.com
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025.
globenewswire.com
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024.
globenewswire.com
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies in tablet form, today announced that the Company will participate at the following conferences.
See all news
